COVID-19 and the nicotinic cholinergic system

The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options. https://bit.ly/2zfUZ1S

Detalles Bibliográficos
Autores principales: Farsalinos, Konstantinos, Angelopoulou, Athina, Alexandris, Nikos, Poulas, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248130/
https://www.ncbi.nlm.nih.gov/pubmed/32444400
http://dx.doi.org/10.1183/13993003.01589-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248130/
https://www.ncbi.nlm.nih.gov/pubmed/32444400
http://dx.doi.org/10.1183/13993003.01589-2020

Ejemplares similares